Skip to content

Novel Biomarkers Related Xuebijing Injection Improves Sepsis

Xuebijing Injection Regulates Endothelial Cell Panapoptosis in Treating Sepsis Through PCDHAC2/BAX/AIM2 Pathway

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06920420
Enrollment
30
Registered
2025-04-09
Start date
2025-03-30
Completion date
2028-12-31
Last updated
2025-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Brief summary

Sepsis is a life-threatening clinical syndrome of organ dysfunction caused by dysregulation of the body's response to infection, and is a common cause of ICU admission for critically ill patients, posing a serious threat to human health. The study demonstrated that hemopexin injection significantly reduced the 28-day all-cause mortality rate of sepsis patients, and this study clarified the specific target and molecular mechanism of hemopexin injection in the treatment of sepsis, which may be of great scientific significance and clinical value for the precise treatment of sepsis and the research and development of new drugs.

Interventions

None listed

Sponsors

Southeast University, China
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

1. Meeting the Sepsis 3.0 diagnostic criteria; 2. SOFA score ≥ 2 and \< 13; 3. Signed informed consent.

Exclusion criteria

1. Age \<18 years or \>75 years; 2. Pregnant or lactating women; 3. Presence of severe primary diseases including malignant tumors severe hematologic disorders and HIV infection; 4. Current use of immunosuppressants or history of organ transplantation within the past 6 months; 5. Comorbidities that significantly affect vascular endothelial structure and function such as acute myocardial infarction.

Design outcomes

Primary

MeasureTime frameDescription
Single-cell transcriptomic analysis of inflammatory and metabolic gene expression, measured using scRNA-seq, with data summarized as differential expression profiles.Day7Single-cell transcriptomic analysis of inflammatory and metabolic gene expression, measured using scRNA-seq, with data summarized as differential expression profiles.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026